EGFR and cancer: Several studies have shown that the EMT may be a determinant of the sensitivity of cancers to several anticancer agents such as EGFR-TKI, 5-flurouracil (5-FU), gemcitabine, and cisplatin 8,10,11,26–28, indicating that cancer cells with acquired resistance to anticancer agents have likely transitioned to a mesenchymal phenotype.